NAPERVILLE, Ill., Nov. 30, 2016 /PRNewswire/ -- Pharmazz, Inc. is a clinical-stage company developing innovative therapeutics in the area of critical care medicine. Results of the human safety and pharmacokinetics of PMZ-2010 were presented at the American Heart Association Scientific Sessions 2016. Abstract titled "Human pharmacokinetics of centhaquin citrate, a novel resuscitative agent" and "Centhaquin citrate improves cerebral blood flow and reduces oxidative stress following hemorrhagic shock in rats" were presented. Pharmazz is developing PMZ-2010 (centhaquin) as a resuscitative agent having a unique property of increasing blood pressure and cardiac output, and decreasing vascular resistance in hemorrhagic shock. In addition, the company is developing PMZ-1620 which is a neuroregenerative agent that produces neurogenesis and angiogenesis in the damaged area of the brain by stimulating endogenous regenerative mechanisms. A human study (CTRI/2016/11/007509) has been initiated to determine the safety and tolerance of PMZ-1620. The company also announced that a Notice of Issuance was received from the US Patent and Trademark Office, for the patent application regarding "Methods for Treatment of Stroke or Cerebrovascular Accidents Using an ETB Receptor Agonist" United States Patent No. 9,493,524 issued on November 15th 2016. In addition, the company declared issuance of patent titled "Method and composition for treating diabetic ketoacidosis" by Canadian Intellectual Property Office on November 29th 2016. In patients with diabetic ketoacidosis high levels of ketone can be dangerously harmful to the body; PMZ-2123 when used with insulin can rapidly lower the blood ketone levels.
"We are pleased to have been granted these Notice of Issuance from the US and Canadian Patent Office," said Dr. Anil Gulati, Inventor and founder of Pharmazz. He added that, "Advancing PMZ-1620 towards human studies is a significant step for the company to develop a novel product that will provide a new simple option for the treatment of patients with (stroke) cerebral ischemia."